X

Trial Profile

Phase Ib/II study of BL-8040 in combination with Atezolizumab in patients with pancreatic cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Motixafortide (Primary)
Indications Pancreatic cancer
Focus Adverse reactions
Sponsors Genentech

Most Recent Events

08 Aug 2017 This trial is part of MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform, according to a BioLineRx media release.
10 Jul 2017 Status changed from planning to recruitingn according to a BioLineRx media release.
01 Jun 2017 According to a BioLineRx media release, Genentech has filed regulatory submissions required to commence this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com